氟哌啶醇治疗谵妄、降低死亡率及预防谵妄发生:贝叶斯与频率学派荟萃分析
该研究纳入7项双盲随机对照试验(1767例)评估氟哌啶醇治疗谵妄、5项(2509例)评估预防谵妄,采用频率学派与贝叶斯分析。贝叶斯分析显示,治疗谵妄时氟哌啶醇降低全因死亡率的临床重要获益概率为68%,减少补救苯二氮䓬类使用的临床重要获益概率为78%,导致严重不良事件的临床重要危害概率仅2%;频率学派分析中,氟哌啶醇较安慰剂减少补救苯二氮䓬类使用的合并风险差为-0.05(95%CI -0.09至-0.00;I²=0%)。预防谵妄时,氟哌啶醇各项疗效结局的临床重要获益概率均低(均<50%),且导致QTc延长的临床重要危害概率为65%。结论支持氟哌啶醇用于成人ICU患者谵妄的治疗,但不支持用于谵妄的预防。
要点
- 贝叶斯分析:治疗谵妄时,氟哌啶醇较安慰剂降低全因死亡率达到临床重要获益(RD<-0.02)的概率为68%。
- 频率学派分析:治疗谵妄时,氟哌啶醇较安慰剂减少补救苯二氮䓬类使用的合并RD为-0.05(95%CI -0.09至-0.00;I²=0%)。
- 贝叶斯分析:预防谵妄时,氟哌啶醇导致QTc延长达到临床重要危害(RR>1.1)的概率为65%。
- 预防谵妄时,氟哌啶醇降低全因死亡率、降低谵妄发生率、减少严重不良事件的临床重要获益概率分别为12%、34%、0%。
- 预防谵妄的频率学派分析中,所有主要和次要结局均无统计学显著性。
适用人群与场景
- 成人ICU患者,用于谵妄的治疗或预防。
研究设计与关键结果
- 研究类型:贝叶斯与频率学派荟萃分析,纳入双盲随机对照试验;治疗谵妄7项(n=1767),预防谵妄5项(n=2509)。
- 治疗谵妄主要结局(贝叶斯分析):氟哌啶醇较安慰剂降低全因死亡率达到临床重要获益(RD<-0.02)的概率为68%,导致严重不良事件达到临床重要危害(RD>0.02)的概率为2%。
- 治疗谵妄次要结局(贝叶斯分析):氟哌啶醇较安慰剂减少补救苯二氮䓬类使用达到临床重要获益(RD<-0.02)的概率为78%;其他所有安全性结局的临床重要危害(RD>0.02)概率均低(均<50%)。
- 治疗谵妄频率学派分析:氟哌啶醇较安慰剂减少补救苯二氮䓬类使用的合并RD为-0.05(95%CI -0.09至-0.00;I²=0%)。
- 预防谵妄(贝叶斯分析):氟哌啶醇降低全因死亡率达到临床重要获益的概率为12%,降低谵妄发生率的概率为34%,减少严重不良事件的概率为0%;导致QTc延长达到临床重要危害(RR>1.1)的概率为65%;所有疗效结局的临床重要获益概率均低(均<50%)。
- 预防谵妄频率学派分析:所有主要和次要结局均无统计学显著性。
证据类型、等级与局限
- 证据类型:贝叶斯与频率学派荟萃分析,纳入双盲随机对照试验。
- 检索数据库:MEDLINE、Cochrane对照试验中心注册库、EMBASE、ClinicalTrial.gov、PubMed,无语言限制,从建库至2024年6月27日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论支持在成人ICU患者中使用氟哌啶醇治疗谵妄,但不支持用于预防谵妄。
- 治疗谵妄时,贝叶斯分析提示氟哌啶醇降低全因死亡率、减少补救苯二氮䓬类使用的临床重要获益概率较高(分别为68%、78%),导致严重不良事件的临床重要危害概率低(2%)。
- 预防谵妄时,贝叶斯分析提示氟哌啶醇导致QTc延长的临床重要危害概率为65%,而各项疗效结局的临床重要获益概率均<50%。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although haloperidol is commonly used to treat or prevent delirium in intensive care unit (ICU) patients, the evidence remains inconclusive. This study aimed to comprehensively evaluate the efficacy and safety of haloperidol for delirium treatment and prevention in ICU patients.
METHODS: We searched MEDLINE, the cochrane central register of controlled trials, EMBASE, ClinicalTrial.gov, and PubMed without language restrictions from database inception to June 27, 2024. We included double-blind randomized controlled trials (RCTs) on haloperidol versus placebo for treating and preventing delirium in adult ICU patients. In addition to frequentist analyses, Bayesian analysis was used to calculate the posterior probabilities of any benefit/harm and clinically important benefit/harm (CIB/CIH). The primary outcomes for delirium treatment were all-cause mortality and serious adverse events (SAEs). For delirium prevention, the primary outcomes included incident delirium, all-cause mortality, and SAEs. The secondary outcomes for efficacy were delirium-or coma-free days, ventilator-free days, length of stay in ICU, length of stay in hospital, and rescue benzodiazepine use. The secondary outcomes for safety were QTc prolongation and extrapyramidal syndrome.
RESULTS: We included seven RCTs on delirium treatment (n = 1767) and five on delirium prevention (n = 2509). The Bayesian analysis showed that, compared to placebo for delirium treatment, haloperidol had a 68% probability of achieving CIB (defined as risk difference [RD] < -0.02) in reducing all-cause mortality, a 2% probability of achieving CIH (RD > 0.02) in causing SAEs, and a 78% probability of achieving CIB (RD < -0.02) in reducing the need for rescue benzodiazepine use. The probabilities of haloperidol causing CIH (RD > 0.02) across all other safety outcomes were low (all < 50%). In frequentist analysis on delirium treatment, the pooled estimated RD for haloperidol compared to placebo was -0.05 (-0.09, -0.00; I2 = 0%) for rescue benzodiazepine use. In Bayesian analysis on delirium prevention, haloperidol had a 12% probability of achieving CIB in all-cause mortality, a 34% probability of achieving CIB in delirium incidence, and a 0% probability of achieving CIB in SAEs. Importantly, haloperidol had a 65% probability of causing CIH (risk ratio > 1.1) for QTc prolongation, while the posterior probabilities of achieving CIB across all efficacy outcomes were low (all < 50%). In frequentist analysis on delirium prevention, all primary and secondary outcomes were not statistically significant in frequentist analysis.
CONCLUSION: Our study supported the use of haloperidol for delirium treatment in adult ICU patients, but not for delirium prevention.
参考来源
- Cheng SL, Hsu TW, Kao YC, et al. Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses. Crit Care. 2025. PMID: 40114217. doi:10.1186/s13054-025-05342-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。